Not every R/s ends badly. Ms7p, (musclepharm)did well after a restructuring. They had product and sales and really did it to appeal to institutional investors. If Mely gets product then who knows this may still explode.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.